A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Discover how metabolic dysfunction-associated steatohepatitis (MASH) damages your liver, its connection to common health ...

The progress made in liver disease research to date presents an opportunity for further advancements in the near future.

Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver ...

Researchers at the University of Oklahoma report a hormone, FGF21, may reverse fatty liver disease by signaling the brain.

(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

Two patients with MASH share their paths to diagnosis, including the challenges they faced and what it took to find answers.

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an investigational GLP-1 weight loss candidate. The stock has not performed well ...

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered ...

Analysts anticipate Altimmune to report an earnings per share (EPS) of $-0.34. The announcement from Altimmune is eagerly ...

Altimmune's webcast to discuss these results and business updates will be held on May 13, 2025, at 8:30 a.m. ET. The market ...